Related Experiment Video
Updated: Jul 12, 2025

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
N-Acetylcysteine Alleviates Phenylephrine-Induced Cardiomyocyte Dysfunction via Engaging PI3K/AKT Signaling Pathway
Sheng-Ping Chao1,2, Wen-Lin Cheng1,2, Wenjuan Yi3
1Department of Cardiology, Zhongnan Hospital, Wuhan University, WuhanChina.
Background:
Increased reactive oxygen species (ROS) and oxidative stress response lead to cardiomyocyte hypertrophy and apoptosis, which play crucial roles in the pathogenesis of heart failure. The purpose of current research was to explore the role of antioxidant N-acetylcysteine (NAC) on cardiomyocyte dysfunction and the underlying molecular mechanisms.
Methods And Results:
Compared with control group without NAC treatment, NAC dramatically inhibited the cell size of primary cultured neonatal rat cardiomyocytes (NRCMs) tested by immunofluorescence staining and reduced the expression of representative markers associated with hypertrophic, fibrosis and apoptosis subjected to phenylephrine administration examined by reverse transcription-polymerase chain reaction (RT-PCR) and western blot. Moreover, enhanced ROS expression was attenuated, whereas activities of makers related to oxidative stress response examined by individual assay Kits, including total antioxidation capacity (T-AOC), glutathione peroxidase (GSH-Px), and primary antioxidant enzyme Superoxide dismutase (SOD) were induced by NAC treatment in NRCMs previously treated with phenylephrine. Mechanistically, we noticed that the protein expression levels of phosphorylated phosphatidylinositol 3-kinase (PI3K) and AKT were increased by NAC stimulation. More importantly, we identified that the negative regulation of NAC in cardiomyocyte dysfunction was contributed by PI3K/AKT signaling pathway through further utilization of PI3K/AKT inhibitor (LY294002) or agonist (SC79).
Conclusions:
Collected, NAC could attenuate cardiomyocyte dysfunction subjected to phenylephrine, partially by regulating the ROS-induced PI3K/AKT-dependent signaling pathway.
Insights
N-acetylcysteine (NAC) reduces heart failure markers in cardiomyocytes by decreasing reactive oxygen species (ROS) and activating the PI3K/AKT pathway. This antioxidant therapy shows promise for treating heart conditions.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Reactive oxygen species (ROS) and oxidative stress contribute to cardiomyocyte hypertrophy and apoptosis, key factors in heart failure pathogenesis.
- Understanding the role of antioxidants in mitigating these cellular dysfunctions is critical for developing new therapeutic strategies.
Purpose of the Study:
- To investigate the protective effects of the antioxidant N-acetylcysteine (NAC) against cardiomyocyte dysfunction.
- To elucidate the molecular mechanisms underlying NAC's action, particularly its impact on oxidative stress and signaling pathways.
Main Methods:
- Primary cultured neonatal rat cardiomyocytes (NRCMs) were treated with phenylephrine to induce dysfunction.
- N-acetylcysteine (NAC) was administered to assess its effects on cell size, hypertrophic/fibrotic/apoptotic markers, and ROS levels.
- Gene and protein expression (RT-PCR, Western blot), antioxidant enzyme activities (T-AOC, GSH-Px, SOD), and PI3K/AKT signaling pathway activation were analyzed.
Main Results:
- NAC significantly inhibited phenylephrine-induced cardiomyocyte hypertrophy, fibrosis, and apoptosis.
- NAC treatment attenuated elevated ROS levels and enhanced the activity of antioxidant enzymes (T-AOC, GSH-Px, SOD).
- NAC increased the protein expression of phosphorylated PI3K and AKT, indicating activation of the PI3K/AKT signaling pathway, which was confirmed to mediate NAC's protective effects.
Conclusions:
- N-acetylcysteine (NAC) effectively attenuates cardiomyocyte dysfunction induced by phenylephrine.
- NAC exerts its protective effects, at least partially, by modulating the ROS-mediated PI3K/AKT signaling pathway.
- These findings highlight NAC's potential as a therapeutic agent for heart failure by combating oxidative stress and regulating key survival pathways.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy V: Interprofessional Care
Cardiopulmonary Resuscitation IV: Pharmacological Management
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: